Glaxo Relents, Grants Mylan Paxil License
The settlement will see the generics maker and its subsidiary, Mylan Pharmaceuticals Inc., receive a patent license by Oct. 1, 2008. It will also see the definitive end to all litigation against Mylan relating to the Paxil CR patent.
Mylan requested Monday that a judge in the U.S. District Court for the...
To view the full article, register now.